Sarepta Therapeutics
SRPT
130 hedge funds and large institutions have $811M invested in Sarepta Therapeutics in 2015 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 14 closing their positions.
153% more capital invested
Capital invested by funds: $321M → $811M (+$490M)
121% more call options, than puts
Call options by funds: $89.5M | Put options by funds: $40.5M
114% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 14
14% more funds holding
Funds holding: 114 → 130 (+16)
13% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$12.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$10.1M |
| 4 |
Jennison Associates
New York
|
+$7.22M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12.4M |
| 3 |
PC
PointState Capital
New York
|
-$3.58M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.27M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.06M |
SRPT Hedge Fund Activity: Q2 2015 in Review
130 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2015, worth a combined $811M — up 153% from $321M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SRPT positions and 14 closed out — a net gain of 16 holders — while 44 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $16.7M. The largest seller was Point72 Asset Management, cutting an estimated $15.7M.
- 130 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2015, up from 114 in Q1 2015.
- Funds reported $811M of Sarepta Therapeutics stock for Q2 2015, up 153% quarter-over-quarter.
- 30 funds opened new Sarepta Therapeutics positions in Q2 2015 and 14 closed out, a net change of +16 holders.
- The largest Sarepta Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $16.7M added.
- The largest Sarepta Therapeutics seller in Q2 2015 was Point72 Asset Management, an estimated $15.7M sold.
Based on aggregated 13F filings for Q2 2015.